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ABSTRACT
PURPOSE
Novel particle engineering approach was used in this study to
generate high dose inhalable effervescent particles with syner-
gistic effects against Pseudomonas aeruginosa biofilms.
METHODS
Spray dried co-amorphous salt of ciprofloxacin (CFX) and
tartaric acid (TA) was prepared and coated with external layer
of sodium bicarbonate and silica coated silver nanobeads.
Design of experiments (DOE) was used to optimize physico-
chemical properties of particles for enhanced lung deposition.
RESULTS
Generated particles were co-amorphous CFX/TA showing
that CFX lost its zwitterionic form and exhibiting distinct
properties to CFX/HCl as assessed by FTIR and thermal
analysis. Particles exhibitedmass mean aerodynamic diameter
(MMAD) of 3.3 μm, emitted dose of 78% and fine particle
dose of 85%. Particles were further evaluated via antimicro-
bial assessment of minimum inhibitory concentrations (MIC)
and minimum biofilm eradication concentration (MBEC).
MIC andMBEC results showed that the hybrid particles were
around 3–5 times more effective when compared to CFX
signifying that synergistic effect was achieved. Diffusing wave
spectroscopy results showed that the silver containing particles
had a disruptive effect on rheological properties as opposed to
silver free particles.
CONCLUSIONS
Overall, these results showed the potential to use particle en-
gineering to generate particles that are highly disruptive of
bacterial biofilms.
KEY WORDS ciprofloxacin . Co-amorphous .
effervescent . dry powder inhaler . Pseudomonas aeruginosa
ABBREVIATIONS
CFX ciprofloxacin
CPF (Coarse particle fraction)
DOE design of experiments
ED (Emitted Dose)
EFPF (Extra-fine particle fraction)
FPD (Fine particle dose)
GSD (geometric standard deviation)
MMAD (mass median aerodynamic diameter)
PFF (Fine particle fraction)
TA tartaric acid
INTRODUCTION
Biofilms are highly dense collection of microbial cells embed-
ded within a self-produced matrix of exopolysaccharide (EPS)
(1). The composition of this bacterial matrix can significantly
vary but generally it is composed of a polysaccharide rich
structure with proteins and DNA (2,3). While this multilayer
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structure is considered resistant to penetration of antibiotics, it
is equally efficient for water and nutrients transports for the
survival of the bacteria (4).Multiple studies have examined the
resistance pathways of bacterial biofilms, but to date there is
no effective technology on how to overcome this mechanism
of drug impedance (5). Pseudomonas aeruginosa is a Gram-
negative bacteria responsible for causing a wide range of nos-
ocomial infections, most notably in immunocompromised
patients. Its ability to form robust biofilms as part of the infec-
tion renders them chronic and difficult to treat hence, there is
an urgent need for synergistic antibiotic therapies (6).
Pulmonary drug delivery using dry powder inhalers (DPIs)
has been widely used to manage respiratory conditions (7).
However, the main challenge with using DPIs is the difficulty
to achieve high levels of the drug inside the lungs (8,9). The
low drug deposition is due to loss of the drug in the throat as
well as in the device itself. Different strategies have been used
to improve the flow properties of the drug particles such as the
use of lactose carrier particles (10–12). This approach is based
on blending the drug particles with the larger carrier particles
which separate inside the device in response to the high inspi-
ratory flow rate generated by the patient (12,13). However,
using carrier particles means the mass of the drug is signifi-
cantly diluted hence this approach cannot be used to deliver
large drug doses. In order to avoid the use of carrier particles,
the drug molecules are combined with co-former molecules to
form co-amorphous dispersions. This approach was used
in this study to form of co-amorphous salts dispersions
where the drug and the co-former interact as twin mol-
ecules forming a glassy solid solution. Advantage of this
approach is the possibility to tailor the properties of the
final particles to target a localised region within the air
conducting zone inside the lungs.
Dental plaques are examples of resistant bacterial bio-
films that adhere to the surface via enhanced viscoelastic
properties (14). The use of effervescent tablets was found
more effective at removing dental plaque than brushing
only (15). Hence, the use of effervescent particles can be
effective method to disrupt bacterial biofilms. Synergism
can also be achieved using silver nanoparticles due to
their antibacterial and mucolytic properties (16).
Ciprofloxacin (CFX) is a poorly water-soluble drug with
broad antibacterial activity and is the drug of choice for
treatment of P. aeruginosa infections. Currently, there are
no inhaled formulations of CFX due to the high doses
needed to achieve therapeutic levels. The aim of this
study is to use an aliphatic acid (tartaric acid) as a co-
former to formulate co-amorphous salt employing spray
drying to produce particles with improved flow properties
and synergistic effects against Pseudomonas aeruginosa. These
will be combined with silver coated silica beads and ex-
ternal layer of sodium bicarbonate to produce effervescent
effect (Fig. 1). Tartaric acid has been shown to produce
central nervous system-mediated bronchodilatation (17)
while organic acids in general have been shown to exhibit
bacteriostatic activity (18). Using design of experiments
(DoE), spray drying conditions were optimised to generate
co-amorphous particles. The formed particles were then
analysed to assess aerodynamic parameters, viscoelastic
properties and antimicrobial activity.
MATERIAL AND METHODS
Materials
CFX (Ciprofloxacin) powder ≥98.0% (HPLC), (CAS: 85721–
33-1) was purchased from Sigma-Aldrich (Dorset UK). TA
(L-(+)-Tartaric acid) crystalline powder, ≥99.7%, CAS: 87–
69-4, was purchased from Sigma-Aldrich (Dorset UK).
Ethanol (99.8%) of analytical grade was obtained from
Sigma-Aldrich (Dorset UK). Tetraethyl orthosilicate (TEOS;
≥99.0%, GC, Sigma-Aldrich), silver (Ag; nanopowder,
<100 nm particle size, 99.5% trace metals basis, Sigma-
Aldrich), dimethylamine (DMA) and sodium bicarbonate
from Sigma-Aldrich. Ultrapure water or high purity lab water
(HPLC gradient grade) was obtained from Fisher Scientific
UK. All other chemicals used were of analytical grade unless
otherwise stated. P. aeruginosa PAO1 (wild type) and
P. aeruginosa NCT10662 were obtained from The University
of Westminster (London, UK) culture collection.
Bacterial strains were all cultured at 37°C. Luria-
Bertani broth and agar (LBB and LBA, Sigma-Aldrich,
Dorset, UK) were used for determination of colony
count for biofilm cell viability assay.
Fig. 1 Schematic showing the structure of prepared microparticles. The shell
incorporates the silica coated silver nanoparticles and NaHCO3 while the
core comprised of the CFX/TA co-amorphous salt.
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Preparation of Co-Amorphous Salt Dispersions Using
Optimised Spray Drying Conditions and Incorporation
of Silica Coated Silver with NaHCO3
Spray-drying experiments were carried out using a spray
dryer B-290 from Büchi (Laboretechnik AG Switzerland)
using nitrogen gas as the drying gas. Mixtures of CFX
(API) with TA (co-former) were prepared using different
molar ratios; 1:1, 1:2, 1:3 and 2:1 with the total weight of
1 g and. The solvents that were used to prepare the sol-
utions were 90% water: 10% ethanol, 80% water: 20%
ethanol, 70% water: 30% ethanol, 60% water: 40% eth-
anol and 100% water. The solutions were then spray
dried using an airflow of 400 L/h, feed rate 10 mL/min
and inlet temperatures 100°C, 120°C, 140°C. The aspi-
ration level was set at 100% and the pump rate at 8 mL/
min and 10 mL/min. The resulting outlet temperature
ranged from 60 to 75°C. The spray-dried product
(powder) was collected from the cyclone collector of the
spray dryer and stored in a vacuum desiccator on silica
gel for further analysis. Samples were then collected and
stored under 0% relative humidity and ambient condi-
tions. Silica coated silver nanobeads were prepared fol-
lowing similar method described before (16). Briefly,
75 mL of ethanol (absolute), 20 mL distilled water and
silver nanoparticles (1 mg) were mixed followed by addi-
tion of 1 mL dimethylamine combined with ultra-sonica-
tion. 1 mL TEOS were added gradually whilst on vigor-
ous stirring using mechanical stirrer. The silica coating
started almost immediately which was observed by in-
creased turbidity of the suspension signifying formation
of the silica around the suspended silver nanoparticles.
The formed suspension of the formed silica coated silver
nanoparticles was added to NaHCO3 solution (prepared
using equimolar concentration to TA) and spray dried
simultaneously using three-fluid nozzle with the CFX/
TA and using similar spray drying conditions described
above. The solutions were kept stirring during spray dry-
ing process to prevent any precipitation.
Powder X-Ray Diffraction (XRPD)
The XRPD pattern scans of pure CFX and TA and all spray
dried samples were collected using a Bruker D8 advance X-
ray diffractometer (Bruker AXS GmbH, Germany). The x-
ray beam is based on a Cu-source, theta diffractometer
equipped with a Lynx eye position sensitive detector.
Brunker D8 Advance was operated at 40 kV generator vol-
tages and 40 mA generator current. The samples were ana-
lyzed using DFFRAC plus XRD commander software
(Bruker AXS GmbH, Germany) with a 2θ range of 5–45°, a
step size of 0.021064112° and time per step of 1.33 s.
Thermal Analysis Using Differential Scanning
Calorimetry (DSC)
Thermal analysis of the co-amorphous dispersion was per-
formed using differential scanning calorimetry (DSC Q2000,
TA instruments, UK). Samples were placed in a crimped al-
uminium pan before being hermetically sealed. A typical ther-
mogram was obtained by initially allowing the sample to
equilibrate at 20°C for 2 min. Samples were then heated up
to 300°C at a heating rate of 10°C/min. All samples were
purged with nitrogen gas flowing at 50 mL/min. The thermo-
grams that were produced were then analysed using Universal
Analysis 2000 (TA instruments).
Fourier Transforms Infrared Spectroscopy (FTIR)
FTIR was carried out to determine molecular interactions
between CFX and TA in each spray dried powder samples.
Perkin Elmer Spectrum One FTIR spectrometer was used to
record infrared spectra of all samples. For each sample, 16
scans were carried out using a resolution of 4 cm−1 and the
scanning mode was set between the frequency range of
4000 cm−1 to 40 cm−1.
Kinematic Viscosity Measurements
The viscosities of solvent mixtures and solutions were mea-
sured using iVisc capillary U-tube viscometer (viscometer con-
stant = 0.001) (Lauda, Königshofen, Germany). Sample solu-
tions were filled into one side of the viscometer and the time
taken to reach the labelled point was measured over time.
Average values of a minimum three measurements were
recorded.
Microrheology Using Diffusing Wave Spectroscopy
(DWS)
Simulation of particles interactions with model biofilm liquid
was studied using glycerol to mimic the biofilm physical prop-
erties. Samples were measured in the Tau Lag and Echo
modes us ing LS Instruments DWS Rheolab (LS
Instruments, Switzerland). Samples were loaded into quartz
cuvette and the Tau lag mode captures data over the higher
measurement frequencies. Tau lag mode captures informa-
tion about the sample over short relaxation timescales whereas
the Echo mode captures the sample response at longer relax-
ation periods (Lower measurement frequencies). This implies
that measurement of the longer relaxation processes can be
collected rapidly (typically 30–60 Seconds). Ultimately, mea-
surement of the loss modulus, storage modulus (G’ and G””)
and complex viscosity were obtained.
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Analysis of Powder Deposition Using Anderson
Cascade Impactor (ACI)
Anderson Cascade Impactor (ACI; Copley Scientific,
Nottingham, UK) was used to analyse the deposition pattern
of DPI formulations. All capsules had the same amount of
CFX dose of 30 mg and were filled in HPMC size 3 capsules
which were loaded in a RS01DPI device prior to testing. Flow
meter was attached to the induction port to verify a flow rate
of 60 L/min. Once flow rate of 60 L/min was achieved the
RS01 DPI device was connected to the induction port which
was then followed by releasing the dose from the device. The
cut-off sizes for the ACI plates using 60 L/min as from stage 1
to stage 8 were as follows: 8.6, 6.5, 4.4, 3.3, 2, 1.1, 0.54 and
0.25 μm. After each run, each ACI stage plate was rinsed with
30 mL 3% acetic Acid. Concentration of CFX was then ana-
lysed using UV spectrophotometer (Jenway, Staffordshire,
UK) at 278 nm absorbance. All experiments were conducted
in triplicate.
Scanning Electron Microscopy (SEM)
Samples were fixed on to the surface of a conductive double-
sided carbon adhesive, attached to an aluminium stub. The
prepared samples were sputter coated with gold, for 3 min at
30mA, using Emitech K550 (Ashford, UK). Themicrographs
were collected using a Philips FEI microscope (Eindhoven,
Netherlands).
Determination of Minimum Inhibitory Concentrations
and Minimum Biofilm Eradication Concentration
Minimum inhibitory concentrations (MIC) and minimum
biofilm eradication concentration (MBEC) of the dispersions
were determined against P. aeruginosa PAO1 and P. aeruginosa
NCTC 10662 strains using a broth dilution method. The
results obtained were interpreted according to guidelines set
by European Committee on Antimicrobial Susceptibility
Testing guidelines. MBEC of the formulations was deter-
mined by the method described by Rudilla et al. with a few
modifications (19). Briefly, pegs with a modified polystyrene
lid (Nunc Immuno TSP system) were immersed into a sepa-
rate 96-well microtiter plate containing 200 μL of LBB inoc-
ulated with P. aeruginosa PAO1 and P. aeruginosa NCTC 10662
per well, respectively. The plates were then incubated at 37°C
for a period of 24 h under static conditions. The pegs were
then rinsed with 0.5 M PBS solution to remove unattached
cells and immersed into a 96-well plate containing CFX sam-
ples and then incubated again at 37°C for a period of 24 h
under static conditions. Bacterial cells from the biofilm were
extracted by sonication for 10 min after an initial wash with
0.5M PBS. The optical density of the recovered bacterial cells
was measured at 600 nm and the data was used to determine
the MBEC. The lowest concentration of the formulation that
prevented the growth of bacterial cells extracted from the
treated biofilm was used to determine the MBEC. All experi-
ments were performed in triplicates.
Biofilm Bacteria Enumeration after MIC Treatment
Biofilms of P. aeruginosa PAO1 and P. aeruginosa NCTC 10662
were grown as mentioned under biofilm quantification by
microtiter plate assay. The microtiter plates were incubated
for 4 h and 12 h at 37°C. After aspiration of planktonic cells
and spent medium, 200 μL of 0.5 M PBS was added to each
well and sonicated for 10 min. On pre-prepared LBA plates,
100 μL of recovered cells were plated and incubated over-
night at 37°C and colonies were counted the following day.
Microtiter Plate Assay for Biofilm Quantification
Biofilms of P. aeruginosa PAO1 and P. aeruginosa NCTC 10662
were formed on 96-well flat bottom polystyrene micro-titre
plates. Bacterial cell suspension was adjusted to 0.5
McFarland standard and 10 μL of the cell suspension was
inoculated into 190 μL of LBB medium with and without
the presence of formulations in their respective wells. The
96-well micro-titre plates were then incubated at 37°C for a
period of 18 h. After aspiration of planktonic cells and spent
medium, the biofilms were stained with 200 μL of crystal
violet solution (0.1%) at room temperature for a period of
5 min. The plates were then gently washed to remove excess
crystal violet and airdried. Finally, the biofilm bound crystal
violet was dissolved in 33% acetic acid and the solution was
measured at O.D 570 nm using a microplate reader (BMG
SPECTROstar Nano).
Pyocyanin and Rhamnolipid Quantification
Pyocyanin quantification was performed based on the method
by Essar et al. with some modifications (20). Quantification
was based on absorbance of pyocyanin at 520 nmunder acidic
conditions after phase separation using chloroform. Biofilms
were resuspended in 1x PBS, then 500 μL of the suspension
was extracted with 3 mL of chloroform and then re-extracted
into 2 mL of 0.2 M HCl to provide a pink to red solution. A
volume of 200 μL of the solution from the samples was then
transferred to a microtiter plate and the absorbance was mea-
sured at 520 nm. Quantification of rhamnolipid was per-
formed by applying the orcinol reaction as described by
Laabei et al. with modifications (21). Briefly, the supernatant
was extracted 3 times with 1 mL diethyl ether prior to com-
pleting evaporation under vacuum.Upon completion, 0.5 mL
of distilled water was added to each of the sample tubes. For
the assay, 100 μL of samples were taken after resuspension in
dH2O. A volume of 900 μL of 0.19% orcinol (diluted in 53%
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H2SO4) was added to the samples and then incubated at 80°C
for 30 min. After incubation, the samples were left to cool at
room temperature and the absorbance was measured at
421 nm. The concentration was determined based on the
standard curve prepared using rhamnose.
Statistical Analysis
Statistical analysis was carried out using JASP software (v 11.1,
Netherlands). Data were analysed using one- and two-sample
Student t tests, or one-way analysis of variance (ANOVA) and
plotted using linear regression and Q-Q analysis. A p value of
≤0.05 was considered significant.
RESULTS
Preparation of Co-Amorphous Ciprofloxacin Tartarate
Using Spray Drying
A mixture of ethanol and water was used to form the silica
coated silver nanoparticle. Initial assessment was undertaken
to optimise the spray drying conditions of the co-amorphous
salt (CFX-TA) to avoid precipitation/crystallization of CFX
during spray drying. We identified three parameters that can
affect the properties of the particles which were: CFX to TA
molar ratio, ratio of ethanol to water in solution prior to spray
drying and inlet temperature. CFX is not soluble in ethanol
hence ratio of ethanol in the solvent system was optimised to
prevent crystallization upon spray drying.
As shown in Fig. 2, increasing the molar ratio of TA
resulted in higher crystallinity. Crystalline peaks could be
detected with some amorphous form formation. XRPD
showed distinct peaks appearing at 9, 18, 19, 21, 25 and
36° which suggests that the formed crystalline structures
are the same regardless of CFX:TA ratio. During spray
drying, the temperature of the droplets is increased to
near/above the boiling temperature of the solvent.
Hence, a temperature range for the spray drying inlet
temperature was selected based on the solvents system,
which was 100, 120 and 140°C. As can be seen in Fig.
2, using lower inlet temperature led to higher crystalline
content with peaks appearing at the same positions men-
tioned above. When the temperature was increased to
140°C the peaks were less distinct indicating formation
of amorphous form. Overall trend revealed that disper-
sions prepared using 100°C showed highest crystallinity
content compared to dispersions prepared using higher
inlet temperatures. It is worth mentioning that a higher
inlet temperature does not necessarily imply optimised
amorphous content as, depending on molar ratio of
CFX to TA, this can lead to rapid evaporation of ethanol
and separation of excess CFX/TA as separate crystals. As
expected, because of low CFX solubility in ethanol, addi-
tion of ethanol in the solvent mixture increased CFX crys-
tallinity. However, the impact on crystallinity content was
less when compared with the impact of changing the mo-
lar ratio of CFX to TA.
A linear regression analysis was performed with crys-
tallinity content (%) being the dependent variable and the
independent variables were: CFX to TA molar ratio, ratio
of ethanol to water in solution prior to spray drying and
inlet temperature (Fig. 3). Crystallinity content was quan-
tified using the area under the peak for each sample di-
vided by the peaks for 100% crystalline CFX. A total of
22 samples were prepared by spray drying and the data
were plotted to find optimum conditions to prepare the
dispersions (Fig. 3). The results showed linear correlation
between inlet temperature and ratio of ethanol used for
spray drying with R2 value of 0.95. This indicates that
when increasing both of those variables, a linear effect
on crystallinity could be observed. Deviation from
Fig. 2 XRPD scans of (A) CFX, TA
and corresponding spray dried dis-
persions of CFX/TA of different
molar ratios, (B) spray dried CFX/
TA (1:2) dispersions prepared using
inlet temperatures of 100, 120,
140°C and (C) spray-dried CFX-TA
dispersions prepared using (i) 10%
v/v ethanol in water solution and (ii)
20% v/v ethanol in water solution.
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linearity was observed when the molar ratio was changed
(with inlet temperature or ethanol ratio) reflected by R2 of
around 0.6. To test regression analysis validity to model
these data, the predicted values were plotted against resid-
uals which showed random distribution of data points
signifying appropriate use of the linear regression
(Fig. 4). Likewise, the Q-Q plot indicated good correlation
between theoretical quantiles and standardized residuals.
Overall, a molar ratio of CFX:TA (1:1) produced co-
amorphous dispersions and was selected to form the hy-
brid microparticles shown in Fig. 1.
As can be seen in (Fig. 5), the particles showed a spher-
ical shape for co-amorphous dispersions of TA to CFX
(1:1) with a smooth surface reflecting the amorphous
Fig. 3 Predicted versus measured
crystallinity content (%) for spray
dried dispersions of CFX and TA
using three pairs of independent
variables: inlet temperature, ethanol
ratio and CFX/TA molar ratio.
Fig. 4 Residual plot analysis of
predicted vs residuals, crystallinity vs
residuals and theoretical quantiles vs
standardized residuals. The bottom
three graphs show residuals analysis
of spray drying conditions: inlet
temperature, ethanol ratio and
CFX/TA molar ratio with relation to
crystallinity content.
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nature of these particles. At CFX: TA 1:2, the shape of
the particles remained spherical with some grove like
structures started to form at the surface. At CFX: TA
1:3, the particles were also spherical with a uniform dis-
tribution of particles size. The impact of solvents compo-
sition was more evident where the shape of the particles
has changed from spherical to irregular shaped particles
with sharp edges especially at higher TA: CFX ratios in
line with the XRPD data shown above. Viscosity data
(Table I) showed that the viscosity of the TA and CFX
solutions varied significantly. Solutions prepared using
water showed kinematic viscosity of 0.840–0.872 mm2/s
while samples prepared using 10% ethanol showed viscos-
ity of 1.096–1.223 mm2/s and for solutions prepared us-
ing 20% ethanol 1.473–1.582 mm2/s. These differences
indicate that the viscosity was twice as high compared to
the viscosity of water solutions, which may explain the
irregular shaped particles formed from ethanolic solutions
(Fig. 5). Lower viscosity is expected to favour more spher-
ical structure for the final particles while higher viscosity
may result in irregular shaped droplets hence final par-
ticles should also be irregular. Higher viscosity could af-
fect the kinetic energy and diffusion of the solvent and
therefore the rate of solvent removal is also affected.
Although ethanol is more volatile, the higher viscosity
combined with lower solubility of CFX led to appearance
of crystals as evident in the XRPD data.
Thermal and Spectroscopic Analysis of CFX/TA
Co-Amorphous Dispersions
The main challenge with measuring thermal events was the
high melting temperature of CFX which leads to degradation
of TA before any melting can be detected. However, thermal
analysis showed that the CFX/TA (1:1) dispersions had a glass
transition temperature (Tg) of 153.5°C. This is significantly
higher than published data for amorphous CFX (87°C) and
tartaric acid (24°C) (22,23). Such high Tg compared to pure
components suggests that the formed dispersion is co-
amorphous salt. This can be demonstrated as deviation from
linear correlation based on Gordon Taylor equation.
In order to understand the nature of intermolecular inter-
actions, FTIR analysis was performed for the spray dried dis-
persions. As can be seen in Fig. 6, the results showed, in agree-
ment with previous studies, stretching of the carboxyl group in
CFX is missing in the region of 1710 cm−1 (23,24). It was
suggested that a “betainelike structure” exists where electronic
effects become more profound leading to the formation of a
Fig. 5 SEM pictures of spray-dried of CFX-TA in different solvent, top samples were prepared in pure water, bottom images refer to dispersions prepared in
10% v/v ethanol in water solution.
Table I Kinematic Viscosity Measurements of Different Ratio with Different
Solvents
CFX:TA Water/ethanol (%) Kinematic viscosity (mm2/s)
1:1 100% 0.84 ± 0.02
1:2 100% 0.86 ± 0.03
1:3 100% 0.87 ± 0.02
1:1 80% /20% 1.52 ± 0.01
1:2 80% /20% 1.53 ± 0.04
1:3 80% /20% 1.47 ± 0.02
1:1 90% /10% 1.19 ± 0.03
1:2 90% /10% 1.22 ± 0.02
2:1 90% /10% 1.09 ± 0.01
1:3 90% /10% 1.11 ± 0.02
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zwitterion, on the carboxyl (COOH). Slight presence of the
zwitterion form could also be seen by the presence of small
peaks in the region of 2200–2400 cm−1 assigned to piperazine
secondary amine. The ionised COO- can still be seen as sym-
metric and asymmetric vibrations at 1585 and 1375 cm−1res-
pectively. The peak at 1611 cm−1 corresponds to the C=O
stretching in the ketone group. The spectrum for TA showed
two peaks at 1717 and 1740 cm−1, which correspond to the
stretching vibrations of the two carbonyl groups on the car-
boxylates. Changing the ratio of the TA to CFX has led to the
loss of the zwitterion structure as the peak at 1585 cm−1 has
disappeared indicating formation of free COOH with a po-
tential to form hydrogen bonds. The peak at 1630 cm−1 is
related to the aromatic carbonyl stretching which has shifted
because of the loss of intermolecular hydrogen bonding. The
carbonyl group in hydroxylate is more acidic and a stretching
could be seen in the region of 1700–1770 cm−1 which has also
overlapped with the peaks of TA. Altering the ratio of CFX to
TA has led to multiple peaks seen within this region indicating
increased bonding at the free COOH combined with less
tendency for self-association reflected in the notable shift at
1630 cm−1. The difference in the pKa values between that of
TA and CFX (secondary amine piperazine) is >5 which
suggests that the formed structures are co-amorphous tartrate
salt. Comparison with CFX hydrochloride salt showed similar
peaks with slight variation potentially due to formed hydrogen
bonds as well as traces of zwitterionic form especially when
ethanol was used.
In order to understand whether the presence of ethanol
affects the ionisation of CFX and possibly the formation
of hydrogen bonds with TA, the spectra for the spray-
dried dispersions prepared were collected (Fig. 7). The
results showed changes in the peaks positions in the region
1650–1800 cm−1 when the solvent was changed from wa-
ter to a mixture of water and ethanol. Three peaks could
be observed at 1715, 1740 and 1760 cm−1, which corre-
sponds to stretching vibration of, bound COOH on TA
and on CFX. Dispersions prepared from water showed a
shift in the peak towards lower frequencies indicating pos-
sible intermolecular bonding with less evident shift in the
peak position for dispersions prepared using 20% ethanol.
Dispersions prepared using similar solvents compositions
but using TA: CFX of 1:1 were also analysed. The differ-
ence among the prepared samples was less clear which
indicates that the impact of solvents was more profound
at higher TA: CFX ratio.
Fig. 6 FTIR spectra of CFX, TA
and corresponding spray dried
dispersions.
Fig. 7 FTIR spectra of CFX, TA
and CFX: TA (1:2) prepared using
different ethanol/water ratios.
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Coating with Silica Coated Silver and NaHCO3
and In Vitro Lung Deposition Studies
The shell of the hybrid particles comprises and NaHCO3 and
silver nanoparticles coated with silica to prevent uncontrolled
aggregation (Fig. 1). This was achieved following similar
method published previously where the silver beads were
coated with silica using Stöber method (16). The findings of
amorphous form formation were carried forward for the prep-
aration of the hybrid particles containing the silica coated
silver core particles. The ratio of CFX:TA (1:1) was used to
form the dispersions while the amount of silver was main-
tained to less than 4–5 ppm in line with our previous findings
(16). The rationale for inclusion of sodium bicarbonate was to
generate effervescent effect so that to penetrate through the
biofilm viscous structure. The particles exhibited similar size
and shape as the co-amorphous CFX/TA signifying success of
forming the particles (Fig. 8). Strong effervescent effect was
initiated in less than 5 s and was completed within 30 s.
Generation of CO2 adds to the synergy of the particles while
attached to the bacterial biofilm allowing the drug to diffuse
freely throughout the viscous network (Fig. 8).
Andersen cascade impactor (ACI) simulates the respiratory
tract, with the ability to modulate flow rate to simulate different
inspiratory flow rates. The induction port represents the throat
with a 90° angle. The ACI body includes 8 stages of progres-
sively smaller nozzle diameters, and therefore, progressively
smaller aerodynamic particle cut-off sizes. This design mimics
the upper and lower respiratory tracts and pulmonary deposi-
tion of inhaled formulations, with a micro-orifice collector
(MOC) acting as a final impaction stage for extremely small
particles. As can be seen in Table II, The spherical hybrid co-
amorphous spray dried particles (that contained silver and so-
dium bicarbonate) showed a mean aerodynamic diameter
(MMAD) of 3.33 μm and GSD of 2.98 μm (Table II). Fine-
particle dose (FPD) is defined as the dose of the inhaled drug
particles with an aerodynamic diameter < 5 μm while fine
particle fraction (FPF) is the ratio of FPD to the total emitted
dose (ED). As can be seen, emitted dose was 23.46 mg (78%)
while FPD was 19.83 mg (85%). Particles prepared with silica
nanoparticles (without silver or sodium bicarbonate) showed
MMAD of approximately 3.8 μm andGSD 2.6 μm. The emit-
ted dose was 24.14 mg (79%) and FPD of 20 mg (82%).
Particles prepared with silica coated silver showed slightly
higher MMAD of or 4.8 μm with GSD of 2.2 μm while the
ED and FPD were 18.2 mg (61%) and 14.8 mg (81%), respec-
tively. When compared with crystalline CFX, ED was signifi-
cantly lower of around 4.5 mg (15%) reflecting significant loss
and poor deposition. There was less variation in the coarse
particle fraction (CFP) among the samples with a median value
of around 19%. The extra fine particle fraction (EFPF) showed
higher variation with the CFX and CFX/TA physical mixture
showing the lowest values of approximately 2.5–6.6% com-
pared with the hybrid particles showing EFPF of 18%. The fine
particle fraction (FPF) was less discriminative among the sam-
ples with highest values were found for the hybrid particles of
84.5%.When comparing theMMAD, it becomes clear that the
hybrid particles exhibited optimum value of 3.33 μm when
compared with CFX (8.05 μm) and CFX/TA physical mixture
(5.3 μm). Particles in the aerodynamic size range from 1.5–
5 μmwere shown to be optimal, as particles <1.0 μm are likely
to be exhaled again while those >5 μm may impact on the
oropharynx (25).
Assessment of Antimicrobial Activity against P. aeruginosa
Assessment of antimicrobial activity against P. aeruginosa was
performed for all formulations containing CFX and TA (1:1
and 1:2). The main characteristic difference between the two
strains of P. aeruginosa used in this study was the level of
mucoidy of the biofilms formed. The mucoidy is dictated by
alginate composition of the biofilm. P. aeruginosa PAO1 in this
respect showed a higher level of mucoidy compared to
P. aeruginosa NCTC 10662 as NCTC 10662 is considered a
Fig. 8 Scanning electron
microscopy image of the spray
dried hybrid microparticles of CFX/
TA with silver coated nanoparticles
incorporating NaHCO3. The effer-
vescence occurred rapidly within
10 s when suspended in water.
Pharm Res          (2020) 37:150 Page 9 of 14   150 
non-mucoid strain. TheMIC andMBEC of CFX:TA 1:1, 1:2
and pure components are shown in Fig. 9. Higher levels of
CFX were required to inhibit P. aeruginosa biofilms as opposed
to planktonic cells. CFX MIC for P. aeruginosa PAO1 was
28 μg/mL, whilst theMBECwas 110 μg/mL. This represents
over a fivefold increase in CFX concentration required for
treatment of biofilms as opposed to planktonic cells.
Notably, MIC for P. aeruginosa for CFX:TA (ratios 1:1 and
1:2) the MIC was found to be 18 μg/mL and 16 μg/mL,
respectively. Biofilm formation of both P. aeruginosa strains
was significantly inhibited by CFX:TA formulations in com-
parison to the control (Fig. 9). CFX:TA formulations were
also more effective compared to CFX at biofilm formation
inhibition (Fig. 9). The stated molar ratios of 1:1 contains
approximately 68% w/w of CFX and 32% w/w TA.
Hence, this suggests that the 1:1 mixtures had MBEC of
around 3.3 times than CFX alone. On the other hand,
CFX:TA molar ratios of 1:2 contains approximately 52.5%
w/w of CFX and 47.5% w/w TA. The latter imply superior
MBEC of around 5.5 times higher than CFX alone.
These results were further supported by the microbial cell
count. It is clearly evident from Fig. 10, that the formulations
used were more effective in reduction of microbial cell count
of P. aeruginosa, especially in the case of P. aeruginosa PAO1,
however the presence of a thicker biofilm also indicates the
retention of pyocyanin and rhamnolipid (Fig. 10). Pyocyanin
and rhamnolipid are two of the virulence factors of
P. aeruginosa that aid in its pathogenicity. However, the formu-
lations used are clearly effective in significantly reducing the
production of rhamnolipid as seen in the case of P. aeruginosa
NCTC 10662 (Fig. 10). Pyocyanin, a phenazine siderophore
is a secondary metabolite produced by P. aeruginosa which pos-
sesses antibacterial activity. The antibacterial activity of pyo-
cyanin is vital and prevalent in P. aeruginosa in the presence of
antagonists as it aids in the survival of the colony of bacterial
cells. The activity of pyocyanin is highlighted in Fig. 10, which
shows that presence of CFX and TA independently or in
formulations did not reduce pyocyanin production due to said
“survival” mechanism of P. aeruginosa.
DISCUSSION
Co-amorphous dispersions are homogenous mixtures that
eliminate the use of carrier particles for pulmonary drug de-
livery. Encapsulation of the co-amorphous salt inside a layer
of silver coated nanobeads and NaHCO3 is a novel approach
for enhancing stability and augment antibacterial properties
due to silver and effervescent effect. Our results showed there
was no signs of premature effervescence signifies that the TA
component did not react with NaHCO3. In order to design
this system, linear regression analysis was undertaken to opti-
mise spray drying conditions.Ta
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Factors that predispose crystallisation depend on molecular
interactions, which are typically stronger than the solvation forces
that exist between water and solutes (26,27). In the CFX and TA
system the most likely intermolecular interactions are ionic and
hydrogen bonds (28). When CFX was mixed with TA solution,
the solubility was enhanced as a result of protonation of CFX
and associated deprotonation of TA. The net outcome would be
equilibrium between the two species where CFX becomes more
soluble as long as the protonation-deprotonation balance is
maintained (29,30). During spray drying, the process involves
rapid removal of water which is associated with crust formation
(solid shell) with water in the core of the droplet (31). This process
is critical for forming co-amorphous CFX/ TA, as at this stage
CFX can precipitate/crystallise out as a separate phase. It was
shown before that the evaporation rate of the solvents can signif-
icantly affect the extent of intermolecular interactions during
spray drying (32).Using ethanol reduces ionic strength and hence
less likely to form the tartrate salt. More importantly, ethanol
serves as an anti-solvent as CFX is practically insoluble in ethanol
and therefore precipitationmay occur. The impact of the solvent
and the used inlet temperature was correlated and a balance
between both was essential to ensure co-amorphous salt was
formed. These two factors were significantly affected by alter-
ation of the molar ratio as shown in regression and residuals
analysis. The impact of spray drying conditions was reflected in
viscosity data where ethanol solutions were more viscous which
likely to promote crystallisation. Incorporation of the silver coat-
ed silica with the NaHCO3 had minimum impact on the mor-
phology as was seen by the SEM images. The formed efferves-
cent effect was very rapid indicating successful design of the par-
ticles. The formed particles exhibited optimum MMAD and
GSD values demonstrating the potential to target bacterially
inhabited regions within the lungs. There have been limited
studies exploring toxicity of inhaled silver nanoparticles, however
with the extremely low amounts of silver used in our study, the
amount delivered is unlikely to cause harm. For example, ho-
meopathic silver preparations can contain 10–15 μg of silver
which is within the range used in this study (16).
The biofilm inhibition and virulence factors assays were per-
formed using the concentrations obtained from MIC and
MBEC data. These implied that the independent data points
(MIC &MBEC) obtained for CFX and TA are used as positive
controls and the effect of the samples will be compared against
them. For example, the data showed that MBEC of CFX:TA
(40 μg/mL) against P. aeruginosa PAO1 which contains ~52.5%
CFX (~21 μg/mL) + 47.5% TA (19 μg/mL) is more potent
compared to independent values for CFX (MBEC of 110 μg/
mL) andTA (MBECof 700μg/mL). So approximately 1/5th of
the total CFX concentration is more potent when used in com-
bination with TA compared to CFX and TA alone. The
Fig. 9 Quantification of biofilm formation by P. aeruginosa PAO1 and NCTC
10662 along with MIC and MBEC.
Fig. 10 Quantification of pyocyanin and rhamnolipid activity by P. aeruginosa
NCTC 10662 and P. aeruginosa PAO1 with and without treatment. Cell
viability of sessile cells present in the biofilm by plating expressed as Log
10 cfu/ ml.
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zwitterion structures of CFX were altered in the CFX:TA,as
could be seen in FTIR, and could possibly enhance the activity
of CFX. The transitional appearance of the cation betaine like
structures (upon dissociation of the salt) and release of CO2 gas
(upon reaction with NaHCO3) are likely to play a pivotal role in
enhanced synergistic effect of these co-amorphous salts.
Microrheology can be used to understand the impact
of the particles on the integrity of the biofi lms.
Microrheology studies were carried out using glycerol at
the suspending medium. Glycerol to simulate bacterial
biofilms was used in previous studies to simulate viscous
contribution of the media (33,34). This is to help under-
stand the impact of particle engineering and inclusion of
the dense silver particles. The prepared particles were
suspended in same volume of glycerol and changes were
monitored for up to 30 min by which different rheological
parameters were recorded and analysed. As can be seen in
Fig. 11, the sample which contained the hybrid micropar-
ticles remained suspended. On the contrary, the sample
which contained no silver has settled rapidly which indi-
cates different viscoelastic properties. Examination of rhe-
ological properties reveals higher complex viscosity of
sample 1 (with silver) than sample 2 (no silver). The loss
moduli were also different with higher loss modulus for
sample 1. This thixotropic effect is likely to cause addi-
tional synergistic effect in disrupting the highly viscous
biofilm structures. These results suggest novel role for
the prepared particles via disruption of the viscoelastic
properties in addition to the effervescence generated due
to interactions between NaHCO3 and TA.
CONCLUSION
In summary, this study represents novel approach in carrier-
free, particle engineering of DPI formulations. The prepara-
tion of CFX:TA formulations by spray drying is a straightfor-
ward process, offering a novel co-amorphous salt without the
use of carriers. This formulation achieved excellent in vitro
deposition performance to target the conducting zone where
P. aeruginosa biofilms are most problematic to eradicate. Most
importantly, the use of TA as a co-former enabled this novel
formulation to have a potent, synergistic effect against
P. aeruginosa biofilms. These CFX:TA formulations could pro-
vide the first inhaled CFX formulation, and offer an addition-
al treatment option for clinicians faced with treating resistant
P. aeruginosa infection.
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Fig. 11 Complex viscosity (Pa.s), moduli (Pa) and loss tangent (G”/G’) of sample 1: spray dried hybrid microparticles with silver nanobeads shell and sample 2:
spray dried microparticles without the silver.
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